SC4: AI-CELERATING BIOPROCESS INFORMATION RESEARCH

MONDAY, AUGUST 12 | 8:30 - 11:00 AM

ABOUT THIS COURSE:

As pharmaceutical research and discovery embarks into the increasingly complex world of biological entities beyond simple monoclonal antibodies, the already daunting landscape of complexity and cost in drug discovery and development expands to a nearly incomprehensible level. In order to work within this vast space, the use of machine learning and cognitive computing techniques is helping to amplify the power, hone the precision, and expand the scale of research by augmenting human capabilities.

WHAT YOU WILL LEARN:

  • We will start with a foundational review of technologies and terms used in order to level set an understanding of what it means to employ Artificial Intelligence. In addition, we will explain what is driving the current momentum behind these technologies to help provide some understanding of why they are important, especially now.
  • We will discuss some of the current and future uses and applications of the technologies to the complicated space surrounding bioprocessing.
  • We will review some of the best practices for getting started in applying these techniques with a special focus on ways in which the nature of bioprocessing is similar and different than the techniques used in other industries or areas.

INSTRUCTOR BIOGRAPHIES:

Bowley_DianaDiana Bowley, PhD, Business Relationship Manager, R&D IR, AbbVie

Diana joined AbbVie in 2012 as a Senior Scientist in Global Biologics. She was involved in many projects driving the design and creation of monoclonal antibodies and bi-specific therapeutics from antibody identification thru CHO cell line development. In 2017 she joined the Information Research team focused on improving business platforms software for Biologics Discovery and Development. Prior to joining AbbVie, Diana’s research efforts focused on antibody discovery and engineering using a phage, yeast and mammalian cell display.

Diana attended the University of Northern Iowa where she received a Bachelor of Science degree in Chemistry. She earned her Doctor of Philosophy in Molecular Biology at The Scripps Research Institute.

Martin_BrianBrian Martin, Senior Principal Data Scientist, Head of AI, R&D IR, AbbVie

Brian joined AbbVie in October of 2018 as the head of the newly formed RAIDERS team within Research & Development’s Information Research division, focused on accelerating, scaling, and amplifying the work of AbbVie’s R&D community using Artificial Intelligence technologies like machine learning, deep learning, and cognitive computing. Brian came to AbbVie after spending five years in technology consulting across many industries, and over a decade of additional experience before that working in trading and financial markets technology. During his consulting time, Brian architected the United States’ Common Securitization Platform and was a founding member of Publicis.Sapient’s AI practice. While his primary focus is AI technologies, his interests are much broader, and he has presented at multiple conferences on topics including optical networking, quantum computing, blockchain, cognitive architecture, and other emerging technology concepts that are all part of digital transformation.

Brian holds a B.S. degree in Computer and Cognitive Science from Alma College and a M.S in Computer Science from the University of Chicago. He is actively involved with technology incubator programs at Mundelein and Lake Forest High Schools, the Creative Destruction Lab at the University of Toronto’s Rotman School, and is a member of the Education Committee for District 115’s Board of Education.